Roth Capital Initiates Coverage on Transition Therapeutics (TTHI) with a Buy
More News related to TTHI
- Transition Therapeutics Announces Dates for Upcoming Corporate Events
- Stem Cell Therapeutics Corp. Announces Third Quarter 2008 Financial Results and Provides Corporate Update
- Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
- Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
- Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Roth Capital initiates coverage on Transition Therapeutics (Nasdaq: TTHI) with a Buy. Price target $14.
Transition Therapeutics Inc. (Transition) is a biopharmaceutical company developing therapeutics for disease indications with large markets.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
